文献速递哮喘

英国普通哮喘人群中重度未控制嗜酸性哮喘的医疗资源使用与费用

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
PubMed 文献 · Thorax · 2017-09-16

结果显示SUEA患病率为0.81%(95%CI 0.78%至0.84%),其人均HCRU及相关费用为全部哮喘患者的3.9倍(95%CI 3.7至4.1)。

要点

  • SUEA在普通哮喘人群中患病率不足1%(0.81%)。
  • SUEA患者哮喘相关HCRU及费用为总体哮喘人群的3.9倍。
  • 需关注重度未控制嗜酸性哮喘的高疾病负担。

核心结论

  • 普通哮喘人群中不足1%的患者为SUEA,但其哮喘相关HCRU和费用显著高于平均水平。

研究设计与样本

  • SUEA定义为基线年内≥2次哮喘发作且血嗜酸性粒细胞计数≥0.3×10^9/L,并在基线及随访年接受LABA和高剂量ICS处方。

主要发现

  • 2940例(0.81%;95%CI 0.78%至0.84%)患者为SUEA。
  • SUEA患者人均HCRU及相关费用为全部患者的3.9倍(95%CI 3.7至4.1)。

关键数值与推荐

  • SUEA定义:基线年内≥2次哮喘发作,血嗜酸性粒细胞计数≥0.3×10^9/L,且基线及随访年接受LABA和高剂量ICS处方。
  • 高嗜酸性粒细胞计数阈值:≥0.3×10^9/L。
  • SUEA患病率:0.81%(95%CI 0.78%至0.84%)。
  • HCRU及费用比值:3.9(95%CI 3.7至4.1)。

临床怎么用

  • 在哮喘管理中应识别符合SUEA定义的高负担患者,其医疗资源使用和费用显著更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the prevalence of severe, uncontrolled eosinophilic asthma (SUEA) and associated costs. AIMS: We sought to determine the prevalence of SUEA and compare asthma-related healthcare resource use (HCRU) and associated costs with overall means for a general asthma population. METHODS: This cohort study evaluated anonymised medical record data (December 1989 through June 2015) from the Clinical Practice Research Datalink and the Optimum Patient Care Research Database to study UK patients with active asthma (diagnostic code and one or more drug prescriptions in the baseline year), aged 5 years and older, without concomitant COPD, and with recorded eosinophil count. SUEA was defined as two or more asthma attacks during 1 baseline year preceding a high blood eosinophil count (≥0.3×109/L) for patients prescribed long-acting β2-agonist (LABA) and high-dosage inhaled corticosteroids (ICS) during baseline plus 1 follow-up year. We compared asthma-related HCRU and associated direct costs (2015 pounds sterling, £) during the follow-up year for SUEA versus the general asthma population. RESULTS: Of 363 558 patients with active asthma and recorded eosinophil count, 64% were women, mean (SD) age was 49 (21) years; 43% had high eosinophil counts, 7% had two or more attacks in the baseline year and 10% were prescribed high-dosage ICS/LABA for 2 study years. Overall, 2940 (0.81%; 95% CI 0.78% to 0.84%) patients had SUEA. Total mean per-patient HCRU and associated costs were four times greater for SUEA versus all patients (HCRU and cost ratios 3.9; 95% CI 3.7 to 4.1). CONCLUSIONS: Less than 1% of patients in a general asthma population had SUEA. These patients accounted for substantially greater asthma-related HCRU and costs than average patients with asthma.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2017. PMID: 28918400. doi:10.1136/thoraxjnl-2017-210531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。